IL6 and atherosclerosis: Evidence has demonstrated that larger or younger platelets might cause prominent adverse effects such as inflammation response and atherosclerosis by elevating the secretion of inflammatory cytokines (such as IL-6 and CRP) compared to older platelets [55].